Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | NOS1 | P29475 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | RAB9A | P51151 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetamide SCHEMBL3323491 | 0.88 | ALDH1A1 (0.60) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Aminothiazole SCHEMBL27899272 | 0.82 | — | — | |
| Aminothiazole SCHEMBL4466019 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Aminothiazole SCHEMBL1003511 | 0.81 | ALDH1A1 (0.68) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Aminothiazole SCHEMBL1241596 | 0.81 | ALDH1A1 (0.75) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Trifluoroacetic Acid SCHEMBL6990558 | 0.79 | ALDH1A1 (0.48) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Aminothiazole SCHEMBL28215372 | 0.79 | ALDH1A1 (0.65) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Aminothiazole SCHEMBL5907075 | 0.79 | ALDH1A1 (0.65) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Aminothiazole SCHEMBL10585434 | 0.79 | ALDH1A1 (0.71) | ALDH1A1TSHRNOS1HSD17B10MEN1 | |
| Trifluoroacetic Acid SCHEMBL27691823 | 0.78 | MEN1 (0.41) | ALDH1A1MEN1KMT2AMAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3814360-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | claimed |
| WO-2023101326-A1 | NOVEL COMPOUND AS AUTOTAXIN INHIBITOR AND USE THEREOF | 주식회사 넥스트젠바이오사이언스 | 2023-06-08 | — | — | WO | disclosed |
| EP-3814360-A1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2021-05-05 | — | — | EP | disclosed |
| CN-102356081-B | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2014-08-27 | — | — | CN | disclosed |
| US-8680113-B2 | BMI-1 protein expression modulators | PTC THERAPEUTICS, INC. (US) | 2014-03-25 | — | — | US | disclosed |
| CN-102356081-A | Bicyclic compounds for the reduction of beta-amyloid production | BRISTOL MYERS SQUIBB CO | 2012-02-15 | — | — | CN | disclosed |
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | PTC THERAPEUTICS, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| CN-101238121-A | Fused bicyclic heterocycle substituted quinuclidine derivatives | ABBOTT LAB (US) | 2008-08-06 | — | — | CN | disclosed |
| EP-1194421-A4 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMA CORP (US) | 2002-09-11 | — | — | EP | disclosed |
| EP-1194421-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001002379-A1 | SELECTIVE NPY (Y5) ANTAGONISTS | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190239-A1 | BMI-1 PROTEIN EXPRESSION MODULATORS | BMI1, CREBBP, BAZ2A | ALDH1A1 2357/4885TSHR 4048/4885NOS1 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.